MindWalk

reefiq turns fragmented biological data into governed, queryable context for ai-enabled drug discovery and biologics development. victoria, british columbia--(business wire)-- mindwalk holdings corp. (“mindwalk”) (nasdaq: hyft), a bio-native ai company, today launched reefiq™, a hyft-powered biological context layer for ai drug discovery and biologics development, that sits between client discovery data and ai reasoning workflows. biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. reefiq reconnects those representations before ai workflows act on them, linking fragmented data into mindwalk's biological representation foundation. sequences, structures, assay outputs, omics, literature, evidence, provenance, and program history are transformed into a governed, queryable connected biological context for ai-enabled discovery. "in life-sciences ai, the durable advantage is not the model a team licenses but the biological context it can reason over. biology is connected by evolutionary constraint; discovery data arrives fragmented across files and systems, and that gap is where insight is lost. reefiq is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files. in a regulated setting, that is what makes reasoning trustworthy, and trustworthy is what compounds into the clinic," said dr. jennifer bath, phd, ceo and president of mindwalk holdings corp. lensai and customer-selected agent models can then retrieve, analyze, and generate hypotheses from connected biological context rather than isolated files. hyft® is mindwalk’s core biological pattern technology. it provides the underlying biological representation foundation with explicit relationships across sequence, structure, function, mechanism, pathway, evidence, and literature. reefiq™ is the client biological context layer built on hyft. it harmonizes client discovery data, links it to mindwalk’s biological representation foundation, preserves provenance and program history, and exposes governed, queryable context to lensai and customer-selected agent models. lensai™ is the reasoning and application layer. it uses reefiq’s connected biological context to support retrieval, analysis, target discovery, candidate diligence, hypothesis generation, and portfolio decision support. hyft powers the biological representation. reefiq organizes and governs the context. lensai applies reasoning workflows. why this layer matters drug-discovery organizations generate valuable context in every program: positive results, negative results, assay conditions, design decisions, mechanism hypotheses, literature links, and reasons candidates did not advance. reefiq preserves that context as governed, queryable knowledge. as data are added, the network is enriched and its relationships and annotations are refined. future programs benefit from the ever-compounding evidence and insights. inspired by cumulative biological systems a reef grows by connecting what came before into a living structure. reefiq uses that metaphor for scientific knowledge: each dataset, result, program, and piece of evidence can become part of a governed context layer for future discovery. “reefiq operationalizes the hyft information network for drug discovery,” said dirk van hyfte, md, phd, chief technology officer of mindwalk. “hyft provides the biological representation foundation, representing the complex relationships in biology; reefiq links customer data to that foundation and exposes governed context to lensai and customer-selected agent models operating within agreed governance. the goal is to support retrieval, analysis, and hypothesis generation over connected biological context while preserving provenance, deployment flexibility, and customer-defined controls.” what comes next reefiq™ is designed to become the foundation for mindwalk's future life-sciences engagements: a hyft-powered biological context layer beneath lensai™ and client-selected model or agent workflows. the architecture supports flexible integration across data governance, model access, and compute deployment. lensai is already in contracted, recurring arrangements with life-sciences customers today. interested parties may request a private briefing through investor relations. for more information about the technology, please visit: https://www.mindwalkai.com/reefiq about mindwalk holdings corp. mindwalk holdings corp. (nasdaq: hyft) is a bio-native ai company building the biointelligence infrastructure that life sciences ai and agentic ai require. its proprietary hyft® system powers reefiq™, the biological context layer for life sciences, a function-aware representation organized around hyft pattern-objects that span sequence and structural biology, refined over 20 years of curation by a continuously evolving knowledge graph of 660 million biological patterns and 25 billion relationships, that enriches data at ingestion and compounds in analytical value with every program run on the platform. the lensai™ platform operates on this infrastructure to enable target discovery, candidate diligence, and portfolio decision support, and to host the agentic ai workflows pharma is racing to deploy. mindwalk's architecture is designed so that the hyft representation layer, not any individual ai model, is the durable, compounding competitive asset. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by terms such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "targets," or similar expressions. forward-looking statements in this press release include, without limitation, statements regarding: the launch and branding of reefiq, the company's biological context layer for life sciences, including trademark clearance of the product name; the characterization of reefiq as a hyft-powered biological context layer that sits between client discovery data and ai reasoning workflows, of hyft as the technology that powers the biological representation, and of lensai as the reasoning and application layer that operates over that context; the description of an architecture intended to support flexible integration across data governance, model access, and compute deployment in regulated life-sciences workflows; the characterization of the knowledge graph's scale (660 million biological patterns and 25 billion relationships) and of reefiq enrichment as compounding in analytical value over time; statements regarding contracted, recurring arrangements with life-sciences customers; and the company's business development objectives. forward-looking statements are based on management's current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially, including: risks relating to the branding, market acceptance, and commercial outcomes of reefiq, including trademark availability and clearance for the reefiq name; the build-out and certification of compliance capabilities for regulated workloads; the ability to convert engagement into contracted arrangements; the technical performance of ai-based discovery methods and of the underlying compute infrastructure; the ability to enter into pharmaceutical, infrastructure, or other partnership arrangements; competition; intellectual property risks; regulatory determinations; and capital markets conditions. additional information is available in mindwalk's annual report on form 20-f and other filings on sedar+ (sedarplus.ca) and edgar (sec.gov/edgar). except as required by law, mindwalk undertakes no obligation to update any forward-looking statement. nothing in this press release constitutes investment advice. this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. trademarks: hyft® is a registered trademark of mindwalk holdings corp. lensai™, reefiq™, hyft base™, hyft matrix™, hyft prime™, and b cell llama™ are trademarks of mindwalk holdings corp. or its subsidiaries. source: mindwalk holdings corp. investor relations, louie toma, cpa, cfa, managing director, coreir, investors@mindwalkai.com source: mindwalk holdings corp.

immunogens designed on the predicted target elicited cross-reactive antibodies against antigens of all four dengue serotypes, reproduced across two independent campaigns hyft® technology computationally identified and prioritized a pan-serotype dengue target before immunization. preclinical data support the prediction at the binding level: immunization with immunogens designed on the predicted target elicited antibodies that cross-react with antigens of all four dengue serotypes, and scrambled-sequence controls support that the response is specific to the designed immunogen rather than background reactivity. austin, texas--(business wire)-- mindwalk holdings corp. (nasdaq: hyft) today reported preclinical dengue data that support a computational prediction its hyft® technology generated before any animal was immunized. hyft® computationally identified a candidate pan-serotype structural target on the dengue virus. the subsequent immunization data support that prediction at the antibody-binding level: animals immunized with immunogens designed on the predicted target generated antibodies that cross-reacted with antigens of all four dengue serotypes — a clear and consistent trend, reproduced at the cohort level across two independent campaigns that used distinct immunogen formats and adjuvants. scrambled-sequence controls did not show the same cross-serotype recognition, indicating the response was specific to the designed immunogen. the result carries implications beyond the dengue program. ai-driven drug discovery depends on biological ground truth — experimentally grounded signal connecting a computational prediction to a measurable outcome in living systems. that substrate has been largely absent from the field: generated inconsistently, outside regulated frameworks, and rarely structured to meet the demands of enterprise ai deployment. the hyft® technology is designed to produce it. today's data are mindwalk's first public evidence that it can. today's data document the platform delivering on its fundamental claim: hyft® technology computationally prioritized the pan-serotype target before immunization, the experiment supported the binding-level prediction, and the experimentally supported target now anchors mindwalk's dengue pipeline ip position as a persistent asset within the company's biointelligence platform. the same predictive capability applied in dengue is being deployed across mindwalk's influenza program and other announced programs where multi-strain coverage presents the analogous design challenge. "the central question for any ai drug discovery platform is whether its computational predictions correspond to real biology," said dr. jennifer bath, phd, chief executive officer and president of mindwalk holdings corp. "hyft® is built to identify functional patterns that are constrained by biophysical reality — patterns that evolution cannot easily escape because they are tied to structural and binding requirements. we identified the dengue target region not because it appeared conserved at the sequence level, but because hyft® recognized it as functionally constrained in a way that conventional sequence analysis would not prioritize. “when animals immunized with immunogens built around that prediction produced antibodies that recognized antigens from all four dengue serotypes — and scrambled-sequence controls did not — the prediction was supported in a live immunological system. that is a closed prediction-to-result loop, and it is the first time we have documented one on this vaccine platform. the antibodies’ functional profile — whether they neutralize virus and how they interact with ade pathways — is what the next body of work will determine. what the current result tells us is that the platform identified real biology. the question now is how broadly that capability holds.” the market: an unsolved pan-serotype problem in a high-burden infectious disease dengue infects an estimated 400 million people annually across four antigenically distinct serotypes. approved dengue vaccines reach only previously seropositive populations because cross-reactive antibodies against one serotype can enhance, rather than neutralize, disease upon first exposure to a second — antibody-dependent enhancement (ade). the unsolved pan-serotype problem has kept a significant portion of the endemic seronegative population outside the addressable market for dengue vaccination, and has made a validated pan-serotype immunogen ip position the critical upstream asset for every next-generation dengue vaccine, broad dengue antibody, and pan-flaviviral platform program in development. identifying that position requires operating below the level of sequence homology. serotype-to-serotype sequence identity across dengue envelope domain iii (ediii) ranges from 74 to 83 percent — high enough to generate broadly cross-reactive antibodies, insufficient to distinguish a functionally constrained pan-serotype target from a cross-reactive decoy. hyft® is designed to make that distinction. rather than relying on sequence alignment or predicted immunogenicity — the parameters conventional target selection leans on — hyft® identifies functional patterns shaped by biophysical constraints: structure, charge distribution, and binding geometry that remain conserved despite evolutionary diversification because biology cannot easily abandon them. within mindwalk's biointelligence platform, these hyft® patterns function as biological anchor points that connect sequence information to structural context, literature-supported biology, and experimental evidence. that connection is made through lensai™, mindwalk's contextualization and reasoning layer, and the company's knowledge graph — a persistent biological intelligence layer that accumulates and links evidence across programs. the significance of the current dengue data is therefore broader than a single dengue vaccine-design experiment: it provides initial experimental evidence for a repeatable discovery loop in which computationally prioritized biological patterns are tested in vivo, and the resulting evidence can be reused across future discovery programs. the current data support cross-serotype antibody recognition at the binding level; future studies will determine whether these antibodies neutralize virus and assess their relationship to antibody-dependent enhancement. “animals immunized with the immunogens we designed around the hyft®-identified target generated antibody responses that recognized antigens from all four dengue serotypes, while scrambled-control immunizations did not show the same cross-serotype recognition profile,” said dirk van hyfte, md, phd, chief technology officer of mindwalk holdings corp. "hyft® computationally prioritized the target region before immunization, and the subsequent antibody-binding data are consistent with that prediction. for mindwalk, the important result is not only the observed binding response, but also the demonstration that computational biological anchors can be connected to structural analysis, immunogen design, experimental readouts, and a reusable evidence layer." platform implications mindwalk's biointelligence platform is built around three complementary components. hyft® identifies biologically meaningful anchor patterns across sequence and structural space. the knowledge graph connects those patterns to structural, functional, literature, and experimental evidence. lensai™ provides the contextualization and reasoning layer that enables scientists and ai models to operate over a common biological representation. together, these components are designed to create a reusable biological intelligence infrastructure rather than a workflow optimized for any single disease program. mindwalk's knowledge graph currently contains hundreds of millions of biological patterns and tens of billions of biological relationships accumulated through years of biological data integration and enrichment. each experimentally supported result contributes additional evidence to this growing representation, strengthening its potential value across future programs in infectious disease, immunology, protein engineering, and therapeutic discovery. the dengue study also demonstrates the platform's ability to identify both broadly conserved and biologically differentiated patterns within the same analytical framework — a capability particularly relevant to discovery programs where balancing broad coverage and selective targeting represents a central design challenge. about mindwalk holdings corp. mindwalk holdings corp. (nasdaq: hyft) is a bio-native ai company building the biointelligence infrastructure that life sciences ai and agentic ai require. its proprietary hyft system functions as the ai-ready data substrate for life sciences -- a function-aware representation organized around hyft pattern-objects that span sequence and structural biology, refined over 15 years of curation by a continuously evolving knowledge graph of 660 million biological patterns and 25 billion relationships, that enriches data at ingestion and compounds in analytical value with every program run on the platform. the lensai platform operates on this infrastructure to enable target discovery, candidate diligence, and portfolio decision support, and to host the agentic ai workflows pharma is racing to deploy. mindwalk’s architecture is designed so that the hyft representation layer -- not any individual ai model -- is the durable, compounding competitive asset. the company operates antibody discovery sites in victoria, british columbia and fargo, north dakota. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by terms such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” or similar expressions, or by statements that certain actions, events, or results are expected to occur or be achieved. forward-looking statements in this press release include, without limitation, statements regarding: the current status and anticipated advancement of the company’s wholly owned pan-serotype dengue program, which is at the preclinical, in vivo proof-of-concept stage; the anticipated characterization of whether the cross-reactive binding antibodies described in this release neutralize virus and of their relationship to antibody-dependent enhancement (ade), as to which no results have been disclosed; the interpretation of the preclinical binding data as supporting a computational prediction generated by the hyft® technology before immunization; the characterization of hyft® pattern-objects and the lensai™ platform as capable of identifying functionally constrained biological targets and of supporting a repeatable discovery loop whose resulting evidence can be reused across future programs; the characterization of the experimentally supported dengue target as a persistent asset within the company’s biointelligence platform and the knowledge graph; the application of the same predictive capability across the mindwalk holdings corp. | nasdaq: hyft | page 4 company’s influenza program and other announced programs where multi-strain or multi-serotype coverage presents an analogous design challenge; the characterization of the knowledge graph’s scale (660 million biological patterns and 25 billion relationships); the anticipated provision of pipeline updates as milestones are reached; and statements regarding the structural, functional, or competitive characteristics of the hyft® biological pattern system and the lensai™ platform. cross-reactive antibody binding observed in preclinical studies does not ensure that such antibodies will neutralize virus, will avoid antibody-dependent enhancement, or will translate into clinical advancement or commercial success of any program. forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially, including: risks relating to the outcome of ongoing and future in vivo studies, neutralization assays, and ade characterization; the ability to advance programs from proof-of-concept to clinical development; regulatory determinations; competition; intellectual property risks; the technical performance of ai-based discovery methods; the ability to enter into pharmaceutical or other partnership arrangements; and capital markets conditions. additional information is available in mindwalk’s annual report on form 20-f and other filings on sedar+ (sedarplus.ca) and edgar (sec.gov/edgar). except as required by law, mindwalk undertakes no obligation to update any forwardlooking statement. nothing in this press release constitutes investment advice. this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. trademarks hyft®, lensai™, hyft base™, hyft matrix™, hyft prime™, and b cell llama™ are trademarks of mindwalk holdings corp. or its subsidiaries. all other trademarks are the property of their respective owners. source: mindwalk holdings corp. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp. (nasdaq: hyft), a bio-native ai therapeutic research and technology company, today announced the launch of its pandemic response platform, a deployment configuration of the company's proprietary hyft® biological pattern system and lensai™ platform purpose-built for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against rna viruses. the platform draws on the same bio-intelligence infrastructure that has supported more than 20 molecules advanced to the clinic across the company's programs, and is currently deployed on its wholly owned pan-serotype dengue and universal influenza programs, both at in vivo proof-of-concept stage, targeting the rna virus categories with the longest history of resisting broadly protective coverage. cross-strain neutralization assays are currently underway for both programs. rna viruses mutate rapidly because replication introduces sequence changes at every cycle; most lack the proofreading mechanisms that dna replication carries, meaning errors accumulate rather than get filtered. surface proteins accumulate those changes fastest, meaning countermeasures built against one variant's surface provide diminishing coverage with each subsequent drift event or species jump. the pandemic response platform bypasses the surface and targets the structural constraints rna biology forces every viable variant to preserve. the platform extends the same constraint-driven discovery engine powering the company's wholly owned pan-serotype dengue and universal influenza programs (both at in vivo proof-of-concept stage, with serotype cross-strain cross-reactivity analyses underway for dengue) into a deployable workflow for governments, biodefense agencies, and pharmaceutical partners. "every outbreak response organized around the surface of a pathogen is a race the pathogen is built to win. we built the pandemic response platform because we believed the only durable answer was to target the architecture the virus cannot change. bundibugyo and andes are not exotic surprises; they are known pathogens in families the conventional countermeasure framework was never designed to cover. our focus now is ensuring the organizations that need this capability can access it,"said dr. jennifer bath, phd, chief executive officer and president of mindwalk holdings corp. the problem rna viruses have resisted broadly protective countermeasures not because the science is young, but because the discovery approach has a structural flaw. the world health organization tracks more than 1,650 epidemic events globally per year. cepi's 100 days mission established the public benchmark that a safe and effective vaccine should be deliverable within 100 days of a disease x pathogen sequence becoming available. the covid-19 experience demonstrated that initial vaccine efficacy does not translate to durable, variant-proof coverage: each major antigenic shift reduced protection against prior formulations and required updated vaccines to recover it. influenza vaccines continue to be reformulated annually. dengue, with four serotypes and a biology that makes antibody-dependent enhancement a real risk, has resisted broadly protective coverage for decades. two active who-declared emergencies in may 2026 make the cost of this gap concrete. across rna virus countermeasure programs, three dynamics have consistently resisted conventional solutions: the target keeps moving. the surface of an rna virus changes fastest. every replication cycle accumulates mutations. vaccines designed against this season's surface are already running behind by the time they reach arms. dengue's four serotypes are the same problem at broader scale: antibodies raised against one serotype can enhance infection by another. influenza does it predictably, necessitating annual reformulation. general-purpose ai inherits the flaw rather than solving it. statistical ai models trained on viral sequence data predict what the next strain might look like based on what past strains looked like. they optimize for sequence similarity to known strains without the ability to distinguish epitopes that are biologically constrained to remain from those that are free to drift. the result is confident target selection against regions the virus is under no evolutionary pressure to preserve. the current bundibugyo ebola outbreak illustrates the consequence: the only approved ebola vaccine was built for the zaire strain. bundibugyo is a structurally distinct species. there is no approved vaccine. candidates are months from human trials. the cost of being wrong resets with every outbreak. strain-reactive vaccines and antibodies deliver narrow protection and expire with every significant drift event or species jump. a discovery substrate anchored to conserved viral architecture compounds in value across every rna virus program run on the same platform, because the conserved core does not expire when the surface changes. “the reason we stay ahead of rna viruses is not processing speed; we work from a different map. conventional discovery asks what the virus currently looks like. hyft encodes what it is constrained to look like, and the knowledge graph has been accumulating those boundaries across rna virus space for 20 years. when a bundibugyo or andes sequence arrives, the constraint data for that pathogen family is already there,” said dirk van hyfte, md, phd, chief technology officer of mindwalk holdings. the technology the pandemic response platform operates on the virus's instruction set: the biological patterns rna viruses must maintain across all viable variants to attach to cells, replicate, and assemble. alter them significantly, and the virus stops working. these constraints are stable against antigenic drift, verifiable across the evolutionary record of rna virus families, and encoded in the knowledge graph's 660 million biological patterns and 25 billion relationships, refined continuously over 20 years of curation. when a novel pathogen sequence arrives, lensai indexes it against that existing constraint data without retraining. no model is built from scratch. the system identifies which regions sit within the constrained core. because candidates are anchored to evolutionary constraint rather than surface similarity to known strains, they are designed to remain relevant across variants the analysis has not yet encountered. about mindwalk holdings corp. mindwalk holdings corp. (nasdaq: hyft) is a bio-native ai company building the bio-intelligence infrastructure that life sciences ai and agentic ai require. its proprietary hyft system functions as the ai-ready data substrate for life sciences, a function-aware representation organized around hyft pattern-objects that span sequence and structural biology, refined over 15 years of curation by a continuously evolving knowledge graph of 660 million biological patterns and 25 billion relationships, that enriches data at ingestion and compounds in analytical value with every program run on the platform. the lensai platform operates on this infrastructure to enable target discovery, candidate diligence, and portfolio decision support, and to host the agentic ai workflows pharma is racing to deploy. mindwalk's architecture is designed so that the hyft representation layer, rather than any individual ai model, is the durable, compounding competitive asset. the company operates antibody discovery sites in victoria, british columbia and fargo, north dakota. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by terms such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "targets," or similar expressions, or by statements that certain actions, events, or results are expected to occur or be achieved. forward-looking statements in this press release include, without limitation, statements regarding: the launch and operational deployment of the pandemic response platform on the company's wholly owned pan-serotype dengue and universal influenza programs; the current status and anticipated advancement of those programs, both at in vivo proof-of-concept stage with cross-strain neutralization assays underway for which no results have been disclosed; the characterization of hyft® pattern-objects and the lensai™ platform as capable of identifying candidates designed to remain relevant across viral variants not yet encountered by the analysis; the compatibility of the platform's design with the cepi 100-day countermeasure timeline; the company's ability to deploy the platform for government, biodefense, and pharmaceutical partners; the anticipated provision of pipeline updates as milestones are reached; the characterization of the knowledge graph's scale (660 million biological patterns and 25 billion relationships) and the company's translational record (more than 20 molecules advanced to the clinic at a discovery success rate exceeding 98 percent); and statements regarding the structural, functional, or competitive characteristics of the hyft® biological pattern system and lensai™ platform. in vivo proof-of-concept results and neutralization assay outcomes do not ensure clinical advancement or commercial success of any program. forward-looking statements are based on management's current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially, including: risks relating to the outcome of ongoing in vivo studies and neutralization assays; the ability to advance programs from proof-of-concept to clinical development; regulatory determinations; competition; intellectual property risks; the technical performance of ai-based discovery methods; the ability to enter into government, biodefense, or pharmaceutical partnership arrangements; and capital markets conditions. additional information is available in mindwalk's annual report on form 20-f and other filings on sedar+ (sedarplus.ca) and edgar (sec.gov/edgar). except as required by law, mindwalk undertakes no obligation to update any forward-looking statement. nothing in this press release constitutes investment advice. this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. trademarks hyft®, lensai™, hyft base™, hyft matrix™, hyft prime™, and b cell llama™ are trademarks of mindwalk holdings corp. or its subsidiaries. all other trademarks are the property of their respective owners. investor relations contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

peer-reviewed study in acs biomacromolecules demonstrates modular vhh potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; mindwalk holds first right to commercialize jointly developed intellectual property austin, texas--(business wire)-- mindwalk holdings corp. (nasdaq: hyft), a bio-native ai company, today announced b cell llama™, a platform for the discovery of vhh nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and car-t cell therapies. bispecific antibody sales alone are projected to reach us$50 billion by 2030, with the broader cell therapy market adding tens of billions more. b cell llama™ is designed to help partners capture this opportunity with better starting material and ai-guided precision at every step of the discovery process. "vhh nanobodies solve the molecular engineering problem that has made bispecific and multispecific drug development so difficult for so long. b cell llama™ extends our flagship b cell select® platform into the distinct biology of llama-derived single-domain antibodies, adding a dedicated vhh capability to the broader mindwalk ecosystem that has supported the advancement of over 15 molecules to the clinic across our technologies. what sets it apart is the ability to layer lensai™ across the entire discovery process: guiding target selection before immunization begins, triaging candidates by predicted function, and evaluating multispecific constructs in silico before a single molecule is built in the lab." dr. jennifer bath, chief executive officer, mindwalk holdings corp. peer-reviewed validation the announcement is anchored by a study published in biomacromolecules (american chemical society, 2026), conducted by mindwalk in a grant-funded collaboration with eindhoven university of technology and radboud university medical center. three findings from the study illustrate what modular vhh design can achieve: potency amplified through assembly. nanobodies displayed in multivalent formats achieved sub-nanomolar potency, 10 to 25 times greater than the same nanobody in monovalent form. modular reconfiguration defeats resistance. a trivalent vhh construct neutralized variants that escaped all monovalent formats and defeated a pair of approved antibody therapies, demonstrating that rational reassembly of the same building block can restore activity where single agents fail. a potential immune-priming effect. vhh-nanoparticle complexes were preferentially internalized by immune cells associated with long-term immune memory, raising the possibility that certain vhh formats may not only neutralize a target but help the immune system recognize it in the future. the study also produced a finding with direct relevance to ai-guided drug discovery: the molecule with the strongest binding affinity delivered zero functional activity. binding strength is not a reliable proxy for efficacy. some conventional discovery workflows depend heavily on binding metrics to rank and select candidates. lensai™ is designed to prioritize function directly. about b cell llama™ b cell llama™ builds on the proven infrastructure of b cell select®, one of the technologies within mindwalk's broader platform ecosystem. where b cell select® isolates antibody-producing b cells from immunized rabbits, b cell llama™ does the same from immunized llamas, capturing vhh nanobodies directly from a naturally matured immune repertoire. this approach accesses a breadth and quality of sequence diversity that synthetic display libraries cannot replicate and that genetically constrained transgenic platforms structurally limit. lensai™ can then be applied across the full workflow: from immunogen design through candidate triage, multispecific construct modeling, and immunogenicity assessment. pipeline context b cell llama™ is one expression of mindwalk's bio-native ai strategy, which is advancing programs across multiple therapeutic areas. current programs include dengue (all four serotypes; advancing to manufacturing), universal influenza (conserved cross-strain target identified), glp-1 and longevity therapeutics (first-in-class dual-pathway regimen; ip protection initiated), and alk-1 (oncology and rare disease). additional programs are in development. about the study le, d.h.t. et al. biomacromolecules 2026, 27(2), 1446-1458. doi: 10.1021/acs.biomac.5c02042. conducted in collaboration with eindhoven university of technology and radboud university medical center, supported by health holland (project lshm20078) under the eureka program. mindwalk holds first right to protect and commercialize jointly generated intellectual property. about mindwalk holdings corp. mindwalk holdings corp. (nasdaq: hyft) is a bio-native ai company transforming the discovery and development of therapeutics, vaccines, and diagnostics. the company's proprietary hyft® technology and lensai™ platform make biological diversity computable and actionable, integrating sequence, structure, function, and literature into a unified computational language. mindwalk's technologies have supported the advancement of over 15 molecules to clinical stage. current programs span dengue, universal influenza, glp-1 and longevity therapeutics, oncology, and nanobody therapeutics. for more information, visit www.mindwalkai.com. forward-looking statements this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995 and applicable canadian securities laws. forward-looking statements include those regarding the capabilities and potential of b cell llama™ and lensai™, pipeline program progress, market projections, and the potential for an immune-priming effect from vhh-nanoparticle formats. lensai™ capabilities described herein represent design intentions and have not all been fully integrated into current operational protocols. preclinical and in vitro results may not translate to clinical success. market estimates are based on third-party projections and may not be realized. the company disclaims any obligation to update forward-looking statements except as required by law. see the company's annual report on form 20-f at www.sedarplus.ca and www.sec.gov/edgar. investor relations: louie toma, cpa, cfa | managing director, coreir | investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp. (nasdaq:hyft) (“mindwalk” or the “company”), a bio-native ai therapeutic research and technology company, today announced an application of its proprietary hyft® technology designed to identify functional adjacency - meaning different molecules can produce the same therapeutic effect even when sequence comparisons suggest they are unrelated - an emerging source of competitive, legal, and valuation risk in modern drug discovery that sequence-alignment-based analysis often fails to capture. using hyft® technology, mindwalk found a shared biological “signature” in influenza that stays consistent even when the virus’s genetic code changes a lot. this supports mindwalk’s approach to designing vaccine targets aimed at broader protection across strains and shows how hyft identifies meaningful similarities in biology even when molecules do not look alike at first glance. “functional adjacency is now one of the most under-appreciated risks in pharmaceutical r&d,” said jennifer bath, ph.d., chief executive officer of mindwalk. “if two molecules deliver the same biological effect, they may compete for the same patient, pursue similar regulatory labels, and undermine perceived differentiation even if their sequences appear unrelated. as ai accelerates protein design, teams can generate many distinct sequences that converge on the same functional outcome, increasing the likelihood of competitive overlap, ip vulnerability, and valuation compression. hyft is intended to help identify this convergence early by evaluating similarity at the functional level, not only at the sequence level.” the functional adjacency problem: an emerging ip risk for pharma functional adjacency, where distinct molecular entities produce the same biological effect despite limited or no sequence similarity, has emerged as a material legal, competitive, and valuation risk in pharmaceutical development. recent u.s. patent decisions have increased scrutiny on broadly drafted, functionally defined claim scope and underscore the need for disclosure and support proportional to what a patent claims. in amgen v. sanofi, the u.s. supreme court found certain broad, functionally defined antibody claims directed to pcsk9 inhibition invalid for lack of enablement, meaning the patent did not teach others how to make and use the full claimed scope without undue experimentation. the decision reinforced a critical reality for biologics, competitive overlap often follows functional equivalence, not sequence similarity, and durable patent protection requires enabling disclosure consistent with the breadth of the claim. similarly, in juno therapeutics v. kite pharma, the federal circuit found certain car-t claims invalid for lack of written description, meaning the patent did not adequately describe the full claimed class of binding elements. the court’s analysis highlighted the risk of claiming broad functional territory without sufficient support, such as representative examples and shared defining features, across the claimed range. together, these decisions reflect an industry shift: multiple molecules achieve the same therapeutic effect through different sequences sequence novelty alone often proves insufficient as a proxy for competitive or legal differentiation competitive landscapes, deal valuations, and ip strategies built primarily on sequence similarity may face increasing fragility as ai-driven protein design accelerates, this challenge intensifies. high-throughput platforms rapidly explore functional space and produce diverse sequences that converge on similar activity, creating blind spots in competitive intelligence and asset valuation when evaluation relies heavily on sequence similarity alone. functional adjacency is no longer theoretical; it is increasingly recognized as an economically material risk, and recent case law underscores its ip implications. hyft technology: functional intelligence beyond sequence alignment hyft technology is designed to help close this gap by identifying conserved functional patterns shaped by biophysical constraints such as structure, charge, and binding interactions, even when evolutionary relationships are unclear and sequence similarity is low. “hyft technology lets us step outside sequence thinking and identify a functional constraint influenza appears to preserve for infection,” said dirk van hyfte, md, ph.d., chief technology officer of mindwalk. in mindwalk’s influenza study, hyft-based analysis identified functional architecture that persisted despite viral mutation, showing how influenza can change its sequence while preserving features required for infection. the same principle applies to ai-designed therapeutics, where optimization can generate diverse sequences that converge on similar functional outcomes. hyft technology is designed to help organizations evaluate competition, ip exposure, and portfolio risk based on functional similarity, where clinical and commercial overlap often occurs. strategic implications for pharma and investors the influenza observation, together with mindwalk’s previously disclosed hyft-enabled dengue epitope program, shows hyft as a cross-pathogen platform for identifying conserved functional design rules in biology, even when targets look different at the sequence level. taken together, these programs support the view that hyft is not a single-asset discovery tool. it is positioned as a scalable strategic intelligence capability within mindwalk’s broader data management and biological reasoning platform. as deployed, hyft is intended to help pharmaceutical and biotechnology organizations: identify potential functional competitors earlier, including ai-designed or convergently evolved assets that sequence-based comparisons may miss strengthen in-licensing and m&a diligence efforts by assessing functional overlap, not only sequence similarity inform patent strategy under heightened scrutiny of function-based claims by grounding how functional space is characterized and supported improve r&d portfolio choices and capital allocation by prioritizing differentiated opportunities and identifying crowded functional areas earlier mindwalk plans to engage pharmaceutical, biotechnology, and other organizations to explore collaborations and commercial arrangements that deploy hyft-based functional intelligence across discovery, diligence, and portfolio decision workflows. this is designed to integrate with mindwalk’s end-to-end data platform, which unifies sequence, structure, function, and literature within a single operational framework. this approach is designed to shift organizations from backward-looking analysis to forward-looking functional decision-making, aligning scientific discovery, competitive intelligence, ip strategy, and capital deployment as ai accelerates therapeutic design. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” “seeks,” “potential,” or similar expressions, or by statements that certain actions, events, or results are expected to occur or be achieved. forward-looking statements in this press release include, without limitation, statements regarding: the interpretation and significance of observations derived from the application of the company’s hyft® technology; the identification, characterization, and relevance of conserved functional patterns and functional adjacency; the hypothesis that such patterns may support rational design toward broadly protective influenza immunogens; the relevance of functional adjacency to competitive intelligence, intellectual property strategy, business development, and portfolio decision-making; the intended role of hyft-based analysis in evaluating functional competition, ip exposure, or portfolio risk; the integration of hyft within the company’s broader data management and biological reasoning platform; the scope, timing, and outcome of potential future validation activities; and the company’s ability to pursue, structure, or complete strategic investments, collaborations, commercial arrangements, partnering transactions, or licensing opportunities related to hyft-based technologies or programs. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. forward-looking statements involve known and unknown risks, uncertainties, and other factors that cause actual results, performance, or achievements to differ materially from those expressed or implied. these factors include, among others: the preliminary and exploratory nature of computational analyses and in silico observations; limitations in available data, inputs, or analytical assumptions; the risk that subsequent laboratory, experimental, or validation studies do not replicate or support the reported observations; uncertainty regarding the biological relevance, robustness, or generalizability of identified functional patterns; risks inherent in therapeutic research and development, including challenges related to translation, validation, manufacturability, safety, immunogenicity, breadth, durability, or efficacy; the risk that future development decisions are delayed, modified, or discontinued; regulatory requirements and uncertainties; dependence on third-party collaborators, laboratories, service providers, and data sources; intellectual property risks, including the ability to obtain, maintain, defend, and enforce patent and other proprietary rights; competitive developments; the availability, timing, and terms of strategic investments or other financing alternatives; the ability to enter into, maintain, or enforce collaborations, partnering arrangements, or commercial agreements on acceptable terms; and broader economic, market, geopolitical, or regulatory conditions. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

study demonstrates selective targeting of misfolded tdp-43 with relevance to amyotrophic lateral sclerosis (als), frontotemporal dementia (ftd), and certain forms of alzheimer’s disease victoria, british columbia--(business wire)-- mindwalk holdings corp. (“mindwalk” or the “company”) (nasdaq: hyft) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic tdp-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (als), frontotemporal dementia (ftd), and certain forms of alzheimer’s disease. this achievement, generated through mindwalk’s integrated discovery engines and research ecosystem, demonstrates the company’s ability to discriminate with structural precision between toxic protein conformations and their essential, healthy counterparts, a long-standing challenge in neurodegenerative disease drug development. by defining the disease-driving structural state and anchoring it in bio-native wet-lab validation, mindwalk is resolving both the structural and functional logic of neurodegeneration and converting that understanding into selective, evidence-linked biological assets. “this discovery is a direct validation of our platform strategy,” said dr. jennifer bath, president and chief executive officer of mindwalk. “we are not just discovering antibodies. we are identifying the disease-defining protein state and translating that insight into selective, validated assets with traceable biological evidence behind them. this is what platform-driven execution looks like in debilitating, life-threatening disease.” mindwalk has demonstrated its ability to generate disease-defining biological assets through the creation of monoclonal antibodies and intrabodies that selectively recognize misfolded, pathogenic tdp-43, a protein implicated in nearly all als cases and a significant portion of ftd and alzheimer’s disease cases. the defining feature of this work is selectivity: the ability to distinguish toxic protein conformations from their healthy counterparts, a key determinant of downstream development risk in neurodegenerative drug programs. beyond the specific biology, this work provides external validation of mindwalk’s platform capabilities in a client-driven setting. it demonstrates the company’s ability to systematically identify and characterize disease-driving protein states and translate that understanding into selective, evidence-linked biological assets. strategically, this strengthens mindwalk’s position as a trusted discovery partner for complex neurodegenerative programs and supports expanded opportunities for future collaborations, repeat engagements, and broader application of its platform across similarly challenging disease areas. “every molecule we characterize today strengthens our evidence base for what defines disease and what distinguishes healthy biology,” added dr. bath. “that compounding, evidence-linked learning is what defines a truly bio-native platform.” the full scientific study, “rational generation of monoclonal antibodies and intrabodies selective for pathogenic tdp-43,” is available on biorxiv (doi: 10.1101/2025.06.10.658846). about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by its patented hyft® technology and lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with a fully integrated wet-lab. the platform enables rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics to convert insight into validated candidates with speed and precision. forward looking statement this press release contains forward-looking statements within the meaning of applicable securities laws. forward-looking statements include statements regarding the significance of the discovery and validation described in this release, the company’s discovery capabilities and platform performance, the potential relevance or application of the monoclonal antibodies and intrabodies referenced, the ability to identify and characterize disease-driving protein states, the potential translation of preclinical findings into future research or development programs, and potential future collaboration, partnering, licensing, or commercialization opportunities. forward-looking statements are based on management’s current expectations and assumptions as of the date of this release and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. these risks and uncertainties include, but are not limited to, the preliminary nature of scientific findings reported in a preprint that has not undergone peer review; the possibility that subsequent peer review, additional experiments, or further analysis may produce different or contrary results; scientific and technical challenges inherent in drug discovery and development; uncertainties regarding reproducibility, selectivity, safety, pharmacology, and manufacturability; uncertainties regarding the translation of preclinical findings into clinical outcomes; regulatory requirements and approval processes; the company’s reliance on third-party collaborators, clients, and partners; intellectual property risks and uncertainties; competitive developments; market and macroeconomic conditions; and the company’s ability to execute its strategy, secure resources, and manage growth. except as required by law, mindwalk undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

validated across influenza a and influenza b, including h3n2 subclade k and zoonotic influenza a subtypes h5, h7, h9 austin, texas--(business wire)-- mindwalk holdings corp. (nasdaq:hyft) (“mindwalk” or the “company”), a bio-native ai therapeutic research and technology company, today announced an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. using its patented hyft® deep data technology, mindwalk identified a functional pattern embedded in influenza biology that remains intact beneath surface-level genetic change. when mindwalk examines what does not change, it is not referring to conserved genetic sequences. it refers to preserved biological constraints; the biophysical requirements influenza must satisfy for infection. influenza remains a major global health threat because influenza viruses continually alter immune-exposed regions of surface proteins, eroding durable protection and forcing reactive vaccine redesign. current u.s. surveillance reflects unusually high influenza activity, described in public reporting as the highest level in approximately 25 years. why influenza keeps beating conventional vaccines most influenza research relies on tracking genetic variation. researchers align sequences, score similarity, and catalog mutations. these methods support surveillance, yet they often miss deeper functional constraints because they operate at the level influenza changes readily. mindwalk’s hyft® pattern technology works without sequence alignment, capturing multi-dimensional functional fingerprints that encode geometry, stability, and biophysical constraints. this reveals functional logic that remains stable even when sequence variation obscures it. this is a layer influenza is constrained from altering without loss of core function required for infection. validation across influenza a subtypes and influenza b lineages using its proprietary hyft pattern framework, mindwalk evaluated the identified functional constraint across influenza a and influenza b datasets spanning multiple hosts. the hyft-defined pattern was confirmed across currently circulating influenza a viruses, including viruses classified within h3n2 subclade k, a genetic subgroup under active global surveillance. the same strict functional pattern was also observed across avian influenza a datasets spanning subtypes h5, h7, and h9, indicating preservation of this constraint across both human and avian influenza backgrounds. mindwalk expanded this analysis beyond influenza a to include influenza b, evaluating representative references from both influenza b lineages, victoria and yamagata, and again observed the same strict hyft-defined functional pattern. in addition, assessment of a representative swine-origin influenza a h1n1 dataset yielded the same result. taken together, mindwalk has now identified this conserved hyft pattern across: influenza a in human datasets, including h3n2 and h3n2 subclade k influenza a in avian datasets, spanning subtypes h5, h7, and h9 influenza a in swine-associated datasets, including h1n1 influenza b across both victoria and yamagata lineages across the influenza datasets evaluated to date, mindwalk has not observed a different way for influenza to meet this functional requirement within the constraints analyzed. these results support the conclusion that the identified pattern reflects an evolutionary constraint shared across influenza a and influenza b, rather than a strain-specific or sequence-dependent feature. “influenza constantly rewrites its genetic script, but it remains tightly constrained by the physics required for infection,” said jennifer bath, ph.d., ceo of mindwalk. “our hyft technology allows us to identify those constraints and design directly against them.” from discovery to biological reasoning and rational vaccine design this advance builds directly on mindwalk’s prior work in rational vaccine design and further supports its bio-native ai and deep data approach. rather than predicting outcomes from incomplete inputs, mindwalk’s lensai™ platform, using the core hyft technology, captures and reasons over biological context, linking sequences, functions, experimental outcomes, and scientific evidence into a continuously learning system. by reasoning directly from biological constraints, mindwalk aims to improve decision quality, reduce downstream failure, and increase the expected value of drug discovery programs. “influenza has been studied for decades, yet researchers kept looking at what changes instead of what does not,” said dirk van hyfte md, phd, chief technology officer of mindwalk. “hyft technology let us step outside sequence thinking and identify a functional constraint influenza must preserve for infection. once you see that layer, the problem stops being about prediction and starts being about design.” influenza program development and out-licensing strategy mindwalk intends to advance its influenza program through a phased, capital-efficient development pathway built around program-level segregation. platform-derived programs are structured as standalone development portfolios, allowing capital, risk, and decision-making to align with each individual asset while preserving the integrity of mindwalk’s core discovery platform. under this approach, the influenza program will progress through additional pre-clinical validation and ind-enabling work within its own dedicated portfolio. this structure is designed to support focused investment, clear value inflection points, and efficient governance as the program advances. following ind-enabling activities and sufficient pre-clinical de-risking, mindwalk plans to out-license the influenza program or enter into strategic development partnerships with global pharmaceutical companies with the scale and infrastructure to advance late-stage development and commercialization. mindwalk also expects to support discussions regarding potential strategic investments and other financing alternatives for the program. about mindwalk mindwalk is a bio-native ai therapeutic research and technology company. through its lensai platform and patented hyft technology, mindwalk generates proprietary biological pattern intelligence designed to support rational vaccine and therapeutic discovery. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” “seeks,” “potential,” or similar expressions, or by statements that certain actions, events, or results are expected to occur or be achieved. forward-looking statements in this press release include, without limitation, statements regarding the company’s influenza research findings and their interpretation; the identification, characterization, and relevance of hyft patterns; the scope of the company’s universal influenza program, including intended breadth across influenza a and influenza b and across seasonal and zoonotic strains; the initiation, design, timing, and results of planned wet-lab validation activities; the ability to translate the reported findings into immunogens, vaccine candidates, or other development assets; the ability to demonstrate immune accessibility, immunogenicity, safety, breadth, and durability in preclinical studies and, if pursued, clinical settings; the timing and outcome of future development decisions; and the company’s ability to pursue, structure, or complete strategic investments, financing alternatives, collaborations, partnering arrangements, or licensing transactions related to the program. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. forward-looking statements involve known and unknown risks, uncertainties, and other factors that cause actual results, performance, or achievements to differ materially from those expressed or implied. these factors include, among others: the preliminary nature of computational analyses and in silico observations; limitations in available data, sampling, and surveillance inputs; the risk that laboratory studies do not replicate or validate the reported findings; uncertainty regarding whether the identified pattern is immune accessible or yields protective immune responses; risks inherent in vaccine discovery and development, including antigen design, formulation, delivery, manufacturability, stability, and scale-up; the risk that a candidate does not demonstrate acceptable safety, tolerability, immunogenicity, breadth, or durability in preclinical studies or clinical settings; the risk of viral evolution and immune escape that reduces effectiveness; regulatory requirements and uncertainties, including requirements for preclinical packages and clinical trial design; dependence on third-party manufacturers, laboratories, collaborators, suppliers, and other service providers; the need for additional capital and the availability, terms, and timing of strategic investments or other financing alternatives; the ability to enter, maintain, and enforce collaborations, partnering arrangements, or licensing transactions on acceptable terms; intellectual property risks, including the ability to obtain, maintain, defend, and enforce patent and other proprietary rights; competitive developments; and broader economic, market, geopolitical, or regulatory conditions. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f, as amended, for the fiscal year ended april 30, 2025, available on the company’s sedar+ profile at www.sedarplus.ca and edgar profile at www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. this press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), bio-native ai company today announces the appointment of industry veteran r. scott areglado as chief financial officer (cfo), effective october 20, 2025. “scott’s extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team,” said dr. jennifer bath, mindwalk ceo. “his proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our bio-native ai platform globally.” mr. areglado brings more than 25 years of financial leadership experience across the healthcare, life sciences, and technology sectors, including extensive expertise in corporate finance, strategic planning, capital markets, and investor relations for publicly traded companies. he has a consistent record of strengthening financial operations, driving revenue growth, and supporting transformative transactions that deliver shareholder value. most recently, mr. areglado served as chief financial officer of brainsway ltd. (nasdaq: bway), a global medical device leader in interventional psychiatry. there, he helped redefine corporate strategy and led eight consecutive quarters of revenue growth while enhancing financial discipline and transparency. he also expanded analyst coverage and investor engagement, strengthening the company’s capital market presence. before joining brainsway, mr. areglado was chief financial officer at icad, inc. (nasdaq: icad), a medical technology company specializing in ai-driven cancer detection and therapy solutions. during his tenure, he successfully led multiple financings totaling more than $50 million, executed strategic partnerships, and supported a series of acquisitions that advanced the company’s product portfolio and market position. earlier in his career, mr. areglado held senior financial roles at amicas, inc. (nasdaq: amcs) and several emerging growth technology companies, where he developed deep expertise in sec reporting, m&a integration, and operational transformation. he began his career in public accounting and holds an mba from babson college and a bba in accounting from the university of massachusetts amherst. mr. areglado added, “mindwalk represents a unique opportunity to apply data-driven financial leadership in support of an organization poised to redefine how ai is applied in life sciences. i am excited to join the team and help advance both our strategic and financial goals as we build long-term value for shareholders.” annual general meeting results and board update mindwalk also announced the results of its 2025 annual general meeting of shareholders, held on october 9, 2025. each of dr. jennifer bath, jon lieber, and dirk witters was elected to the company’s board of directors, and davidson & company llp was re-appointed as auditor for the ensuing fiscal year. in accordance with the company’s majority voting policy, mr. kamil isaev, having received approximately 32% of votes in favor and 68% withheld for his re-election, has tendered his resignation to the board. the board has accepted mr. isaev’s resignation, effective immediately, and wishes to thank him for his valuable contributions to mindwalk’s transformation into a bio-native ai leader. mindwalk will file the complete voting results of the 2025 agm on sedar+ and on form 6-k with the u.s. securities and exchange commission. the board is initiating a search process to fill the resulting vacancy and will provide an update once a successor has been appointed, consistent with the company’s governance framework about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.

austin, texas--(business wire)-- mindwalk holdings corp.™ (“mindwalk,” “company,” “we” or “us”) (nasdaq: hyft), a bio-native ai company today announced the appointment of industry veteran thomas w. lynch, ph.d. as chief business officer (cbo), effective october 20, 2025. “tom’s combination of biotech depth and software commercialization expertise directly supports mindwalk’s next path of growth,” said dr. jennifer bath ceo of mindwalk. “as we expand the reach of our hyft-powered deep data platform across pharma and biotech markets worldwide, tom’s leadership in scaling global teams and forging strategic partnerships will be instrumental in creating long-term shareholder value.” dr. lynch is an accomplished industry leader with over two decades of experience focused at the intersection of biotechnology and software innovation. dr. lynch has a strong track record in scaling global commercial organizations, launching high-impact products, and driving market adoption of advanced software and data platforms. his career spans technical sales, client services, and business development, where he has consistently delivered growth by combining deep scientific understanding with disciplined commercial execution. most recently, dr. lynch served as director of technical sales & scientific support at aldevron, where he built and led a new global commercial team, aligning strategies with scientific innovation and client needs. prior to that, as vice president of global sales and client services, dr. lynch spearheaded key initiatives including the introduction of clinical mrna manufacturing services and strategic account expansion that materially advanced aldevron’s market position. these efforts were instrumental in accelerating growth and positioning aldevron for its $9.6b acquisition by danaher life sciences in 2021. earlier in his career, dr. lynch led global commercial operations at dnastar, overseeing sales, distribution, and technical support while successfully launching software products that advanced protein structure prediction and analysis, such as novafold powered by i-tasser. his achievements underscore a proven ability to successfully bring complex scientific software and data platforms to market. dr. lynch also serves on the board of bioforward, wisconsin’s leading biohealth association, where he helped drive industry collaboration, education, and legislative initiatives across wisconsin’s biohealth sector. dr. lynch added: “mindwalk sits at the frontier of ai-native data intelligence in life sciences. i am excited to help accelerate the company’s growth trajectory by translating its powerful technology into solutions that drive measurable value for customers, partners, and investors alike.” mindwalk’s appointment of dr. lynch marks another step in executing its commercial strategy to broaden adoption of its bio-native ai platform, positioning the company to capture a growing share of the multibillion-dollar life sciences data analytics market. about mindwalk mindwalk is a bio-native ai company transforming drug discovery and development. powered by patented hyft® technology and the lensai™ platform, mindwalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. the platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. forward-looking statements this press release contains forward-looking statements within the meaning of applicable united states and canadian securities laws. forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. these include, but are not limited to, statements regarding mindwalk’s appointment of dr. thomas w. lynch as chief business officer; the expected impact of this appointment on the company’s commercial strategy and growth trajectory; the scalability and adoption of mindwalk’s hyft® technology and lensai™ platform; and the company’s ability to expand its bio-native ai solutions across pharmaceutical and biotechnology markets. forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and company performance. actual results could differ materially from those expressed or implied due to factors beyond the company’s control, including: risks related to the execution of commercial and strategic initiatives; challenges in scaling ai-enabled software adoption in complex enterprise environments; scientific or technical development risks; market acceptance of the company’s technologies; competitive pressures; intellectual property protection; and general economic, regulatory, or geopolitical conditions. forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. additional information about these and other risks and uncertainties is set out in the company’s annual report on form 20-f for the fiscal year ended april 30, 2025, available on the company’s profiles at www.sedarplus.ca and www.sec.gov/edgar. readers are cautioned not to place undue reliance on forward-looking statements. except as required by applicable law, mindwalk undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise. investor contact louie toma, cpa, cfa managing director, coreir investors@mindwalkai.com source: mindwalk holdings corp.